---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-027241"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2025-08-18T23:59:59+00:00"
generated_at: "2026-05-17T11:57:03.085191+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Moleculin shareholders approve 5x authorized share increase and reverse split authority

## Summary
- Authorized common shares increased from 100M to 500M (Proposal 8).
- Reverse stock split up to 1:20 authorized (Proposal 9); timing not disclosed.
- Share issuance for June 23, 2025 warrants (up to 148.7M shares) approved (Proposal 6).
- Equity incentive plan shares increased (Proposal 3); say-on-pay approved (Proposal 4).
- Supermajority voting amendment failed (Proposal 7); all 6 directors re-elected.

## SEC filing metadata
- accession: 0001437749-25-027241
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2025-08-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774925027241/0001437749-25-027241-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774925027241/mbrx20250818c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-027241
- JSON: https://secwatch.observer/filing/0001437749-25-027241.json
- Plain text: https://secwatch.observer/filing/0001437749-25-027241.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.